🇯🇵·8h agoIndustry
Chugai Obtains Approval for FoundationOne CDx Cancer Genomic Profile as a Companion Diagnostic of Tovorafenib for BRAF V600 Alterations and BRAF Fusion Gene-Positive Glioma
Publisher
C
Chugai Pharmaceutical
Japan
This page provides publisher metadata, and related coverage to support discovery before sending readers to the original article.
Read originalAt a glance
- Publisher
- Chugai Pharmaceutical
- Region
- Japan
- Scope
- Industry
- Published
- September 16, 2026
Publisher context, original article off-platform
This page presents the title, publisher metadata, and related coverage. The publisher did not provide a public summary in this feed. Full-text reading stays on the publisher's original site.
Source route
Continue on chugai-pharm.co.jp
Leave the platform to read the original full article on the publisher site.
Source: Chugai Pharmaceutical
Scope: Industry
Related coverage
More related coverage
Bristol-Myers Squibb News/3h ago
Bristol Myers Squibb Announces Dividend
Certara/6h ago
Toward Canonical HELM Representations for Sequence-Level Peptide Registration
Chugai Pharmaceutical News/8h ago
FoundationOne CDx がんゲノムプロファイル、BRAF V600変異及びBRAF融合遺伝子陽性の神経膠腫に対するトボラフェニブのコンパニオン診断として承認を取得
WuXi Biologics/6h ago